+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia



Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia



Journal of Pathology 184(4): 396-400



Experimental studies suggest that cyclin D1 is a potential oncogene but in clinical studies of invasive breast cancer, overexpression of cyclin D1 is found to be associated with oestrogen receptor (ER) expression and low histological grade, both markers of good prognosis. Immunohistochemistry has been used to examine the relationship between cyclin D1 expression and differentiation in 36 cases of ductal carcinoma in situ (DCIS) and the interrelationship between expression of cyclin D1, its associated protein product of the retinoblastoma gene (pRb), and ER, in this group of cases. The expression of these markers has also been examined in nine cases of atypical ductal hyperplasia (ADH) and these results have been compared with the levels of expression seen in DCIS. Cyclin D1 overexpression was found in 23/36 (64 per cent) cases of DCIS and, in contrast to invasive carcinoma, there was no relationship with either differentiation or ER expression. The level of pRb expression was significantly associated with cyclin D1 expression (rs = 0.49, P = 0.001) and only two cases (6 per cent) were pRb-negative. There was no association between pRb and differentiation of DCIS or ER status. In contrast to DCIS, only one case of ADH showed overexpression of cyclin D1 (Mann-Whitney U-test, P = 0.02). All cases of ADH were ER-positive and showed moderate pRb staining, similar to that seen in well-differentiated DCIS. These results provide further evidence that overexpression of cyclin D1 plays a role early in carcinogenesis.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008406962

Download citation: RISBibTeXText

PMID: 9664905

DOI: 10.1002/(sici)1096-9896(199804)184:4<396::aid-path1259>3.0.co;2-g


Related references

Cyclin D1 expression in ductal carcinoma in situ, atypical ductal hyperplasia and usual ductal hyperplasia: An immunohistochemical study. Pathology International 50(7): 527-530, July, 2000

Cell cycle proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. Journal of Pathology 181(SUPPL ): 21A, 1997

Cyclin D1 expression in usual hyperplasia, atypical ductal hyperplasia and low nuclear grade ductal carcinoma in situ of the breast An immunohistochemical study. Journal of Pathology 187(SUPPL ): 25A, 1999

Expression of cyclin-dependent kinase inhibitor, p27 in ductal carcinoma in situ and atypical ductal hyperplasia of breast. Laboratory Investigation 78(1): 22A, 1998

Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ. Archives of Pathology & Laboratory Medicine 140(7): 686-689, 2016

Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. Journal of Pathology 198(4): 458-467, 2002

Thymidine kinase 1 expression in atypical ductal hyperplasia significantly differs from usual ductal hyperplasia and ductal carcinoma in situ: A useful tool in tumor therapy management. Molecular Medicine Reports 2(6): 923-929, 2009

Expression of cyclins in ductal hyperplasia, atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Yonsei Medical Journal 41(3): 345-353, 2000

Differences and Relationships Between Normal and Atypical Ductal Hyperplasia, Ductal Carcinoma In Situ, and Invasive Ductal Carcinoma Tissues in the Breast Based on Raman Spectroscopy. Applied Spectroscopy 71(2): 300-307, 2017

Clinical, radiographic, and pathologic correlation of atypical hyperplasia, ductal carcinoma in situ, and ductal carcinoma in situ with micro-invasion. Breast 2(1): 21-26, 1993

Comparison of rate limiting factors in the transformation of atypical ductal hyperplasia and ductal carcinoma in situ of the breast using immunohistochemistry and fluorescence in situ hybridization. Modern Pathology 16(1): 50A, January, 2003

Ductal carcinoma in situ and bilateral atypical ductal hyperplasia in a 23-year-old man with gynecomastia. American Surgeon 77(9): 1272-1273, 2011

CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia. Breast Cancer Research and Treatment 84(3): 247-250, 2004

Atypical ductal hyperplasia and ductal carcinoma in situ of the breast associated with perineural invasion. Human Pathology 32(8): 785-790, 2001

TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment 41(2): 103-109, 1996